Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$40.81 +2.1%	$27.46	$16.50 ▼ $40.81	$3.48B	N/A	14,395 shs	14,448 shs
ARDX Ardelyx	$3.68 +1.4%	$4.02	$3.21 ▼ $8.06	$868.50M	0.59	4.50 million shs	2.87 million shs
PTGX Protagonist Therapeutics	$55.22 +1.4%	$48.59	$31.34 ▼ $60.60	$3.37B	2.25	897,698 shs	824,720 shs
SRRK Scholar Rock	$35.48 -0.9%	$32.01	$6.76 ▼ $46.98	$3.40B	0.28	1.29 million shs	848,789 shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	+2.05%	+13.74%	+58.06%	+88.50%	+4,080,999,900.00%
ARDX Ardelyx	+1.38%	+1.94%	-7.30%	-25.35%	-39.77%
PTGX Protagonist Therapeutics	+1.43%	+2.41%	+18.93%	+12.97%	+73.87%
SRRK Scholar Rock	-0.92%	-2.31%	+16.44%	+8.04%	+352.55%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ARDX Ardelyx	4.0907 of 5 stars	3.5	1.0	0.0	4.4	2.7	2.5	0.6
PTGX Protagonist Therapeutics	1.2242 of 5 stars	2.5	2.0	0.0	0.0	1.5	2.5	0.0
SRRK Scholar Rock	3.9747 of 5 stars	2.6	2.0	0.0	4.4	3.0	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAPG Ascentage Pharma Group International	3.00	Buy	N/A	N/A
ARDX Ardelyx	3.00	Buy	$10.89	195.89% Upside
PTGX Protagonist Therapeutics	3.00	Buy	$66.10	19.70% Upside
SRRK Scholar Rock	3.14	Buy	$42.67	20.26% Upside

Current Analyst Ratings Breakdown

Latest ARDX, PTGX, AAPG, and SRRK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	ARDX Ardelyx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
6/18/2025	SRRK Scholar Rock	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$50.00
6/17/2025	PTGX Protagonist Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$72.00
6/3/2025	PTGX Protagonist Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
6/3/2025	SRRK Scholar Rock	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/19/2025	PTGX Protagonist Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/14/2025	SRRK Scholar Rock	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$50.00
5/2/2025	ARDX Ardelyx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
5/2/2025	ARDX Ardelyx	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$11.00
4/10/2025	PTGX Protagonist Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
3/28/2025	PTGX Protagonist Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$70.00 ➝ $70.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAPG Ascentage Pharma Group International	$134.35M	26.46	N/A	N/A	$0.48 per share	85.02
ARDX Ardelyx	$333.61M	2.64	N/A	N/A	$0.73 per share	5.04
PTGX Protagonist Therapeutics	$434.43M	7.88	$4.58 per share	12.05	$11.33 per share	4.87
SRRK Scholar Rock	$33.19M	101.50	N/A	N/A	$3.94 per share	9.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAPG Ascentage Pharma Group International	-$55.54M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ARDX Ardelyx	-$39.14M	-$0.22	N/A	11.87	N/A	-14.86%	-34.45%	-13.81%	7/30/2025 (Estimated)
PTGX Protagonist Therapeutics	$275.19M	$0.75	73.63	N/A	N/A	27.04%	9.22%	8.31%	8/5/2025 (Estimated)
SRRK Scholar Rock	-$246.29M	-$2.53	N/A	N/A	N/A	N/A	-118.22%	-82.01%	8/6/2025 (Estimated)

Latest ARDX, PTGX, AAPG, and SRRK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	SRRK Scholar Rock	-$0.63	-$0.67	-$0.04	-$0.67	N/A	N/A
5/6/2025	Q1 2025	PTGX Protagonist Therapeutics	-$0.50	-$0.19	+$0.31	-$0.19	$30.44 million	$28.32 million
5/1/2025	Q1 2025	ARDX Ardelyx	-$0.10	-$0.17	-$0.07	-$0.17	$79.40 million	$74.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAPG Ascentage Pharma Group International	3.24	1.26	1.26
ARDX Ardelyx	1.04	4.12	3.81
PTGX Protagonist Therapeutics	N/A	17.25	17.26
SRRK Scholar Rock	0.16	10.25	10.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAPG Ascentage Pharma Group International	N/A
ARDX Ardelyx	58.92%
PTGX Protagonist Therapeutics	98.63%
SRRK Scholar Rock	91.08%

Insider Ownership

Company	Insider Ownership
AAPG Ascentage Pharma Group International	N/A
ARDX Ardelyx	4.80%
PTGX Protagonist Therapeutics	4.90%
SRRK Scholar Rock	13.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAPG Ascentage Pharma Group International	600	87.12 million	N/A	N/A
ARDX Ardelyx	90	239.26 million	227.77 million	Optionable
PTGX Protagonist Therapeutics	120	61.98 million	58.95 million	Optionable
SRRK Scholar Rock	140	94.95 million	82.32 million	Optionable

ARDX, PTGX, AAPG, and SRRK Headlines

Recent News About These Companies

Jeffrey S. Flier Sells 11,136 Shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) Stock

June 26 at 6:57 AM | insidertrades.com

Jeffrey S. Flier Sells 11,136 Shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) Stock

June 25 at 5:46 PM | marketbeat.com

Insider Selling: Scholar Rock Holding Corporation (NASDAQ:SRRK) Director Sells 20,316 Shares of Stock

June 25 at 5:46 PM | marketbeat.com

Scholar Rock (NASDAQ:SRRK) Shares Up 5.2% - Time to Buy?

June 25 at 2:21 PM | marketbeat.com

Scholar Rock Holding Corp. (SRRK) Stock Price Today - WSJ

June 24 at 8:47 PM | wsj.com

Scholar Rock Holding Corp News (SRRK) - Investing.com

June 24 at 8:47 PM | investing.com

Scholar Rock CEO on its drug that could preserve muscle in weight-loss drug users

June 24 at 7:14 PM | youtube.comY

Scholar Rock: EMBRAZE Results Drive The Stock Higher

June 23, 2025 | seekingalpha.com

Scholar Rock (NASDAQ:SRRK) Trading Down 5.7% - Time to Sell?

June 22, 2025 | americanbankingnews.com

Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Recommendation of "Buy" from Brokerages

June 21, 2025 | americanbankingnews.com

Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Recommendation of "Buy" from Analysts

June 21, 2025 | marketbeat.com

Scholar Rock (NASDAQ:SRRK) Shares Down 5.7% - Should You Sell?

June 20, 2025 | marketbeat.com

Scholar Rock (SRRK) Jumps 16.6% After Successful Weight Loss Drug Trial

June 19, 2025 | insidermonkey.com

Scholar Rock data show promise for muscle-preserving combo with Zepbound

June 19, 2025 | thepharmaletter.comT

Scholar Rock (NASDAQ:SRRK) Given Outperform Rating at Wedbush

June 19, 2025 | americanbankingnews.com

Scholar Rock (NASDAQ:SRRK) Receives Outperform Rating from Wedbush

June 18, 2025 | marketbeat.com

Scholar Rock says its drug preserved lean mass in patients taking Zepound

June 18, 2025 | statnews.comS

Scholar Rock Jumps on Weight Loss Data for Zepbound/Repurposed Antibody Combo

June 18, 2025 | biospace.comB

Scholar Rock's SMA drug helps weight loss patients on Zepbound retain muscle in phase 2 trial

June 18, 2025 | fiercebiotech.comF

Scholar Rock stock soars after drug shows promise in preserving lean mass during weight loss

June 18, 2025 | au.investing.com

Scholar Rock lead asset causes higher quality weight loss with Lilly’s obesity drug

June 18, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARDX, PTGX, AAPG, and SRRK Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

$40.81 +0.82 (+2.05%)

As of 06/26/2025 04:00 PM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

Ardelyx NASDAQ:ARDX

$3.68 +0.05 (+1.38%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$3.70 +0.01 (+0.41%)

As of 08:05 AM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Protagonist Therapeutics NASDAQ:PTGX

$55.22 +0.78 (+1.43%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$55.31 +0.09 (+0.16%)

As of 04:11 AM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Scholar Rock NASDAQ:SRRK

$35.48 -0.33 (-0.92%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$36.17 +0.69 (+1.94%)

As of 08:04 AM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time